| 1. | 1 Guyatt GH, Oxman AD, Kunz R, 
et al . GRADE guidelines: Introduction - GRADE evidence profiles and summary of findings tables. J Clin Epidemiol , 2011, 64: 383-394. | 
				                                                        
				                                                            
				                                                                | 2. | Guyatt GH, Oxman AD, Kunz R, et al . GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol , 2011, 64: 395-400. | 
				                                                        
				                                                            
				                                                                | 3. | Guyatt GH, Oxman AD, Vist GE, et al . GRADE guidelines: 4. Rating the quality of evidencedstudy limitations (risk of bias). J Clin Epidemiol , 2011, 64: 407-415. | 
				                                                        
				                                                            
				                                                                | 4. | Guyatt GH, Oxman AD, Montori V, et al . GRAD Eguidelines: 5. Rating the quality of evidence – publication bias. J Clin Epidemiol , In press. | 
				                                                        
				                                                            
				                                                                | 5. | Guyatt GH, Oxman AD, Kunz R, et al . GRAD Eguidelines: 6.Rating the quality of evidence-imprecision (random error). J Clin Epidemiol , In press. | 
				                                                        
				                                                            
				                                                                | 6. | Guyatt GH, Oxman AD, Kunz R, et al . GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol , In press. | 
				                                                        
				                                                            
				                                                                | 7. | Guyatt GH, Oxman AD, Kunz R, et al . GRADE guidelines: 8. Rating the quality of evidence-indirectness. J Clin Epidemiol , In press. | 
				                                                        
				                                                            
				                                                                | 8. | Waldman RJ, Hall WN, McGee H, et al . Aspirin as a risk factor in Reye’s syndrome. JAMA , 1982, 247: 3089-3094. | 
				                                                        
				                                                            
				                                                                | 9. | Starko KM, Ray CG, Dominguez LB, et al . Reye’s syndrome and salicylate use. Pediatrics , 1980, 66: 859-864. | 
				                                                        
				                                                            
				                                                                | 10. | Halpin TJ, Holtzhauer FJ, Campbell RJ, et al . Reye’s syndrome and medication use. JAMA , 1982, 248: 687-691. | 
				                                                        
				                                                            
				                                                                | 11. | Hurwitz ES, Barrett MJ, Bregman D, et al . Public health service study of Reye’s syndrome and medications: report of the main study. JAMA , 1987, 257: 1905-1911. | 
				                                                        
				                                                            
				                                                                | 12. | Kearon C, Gent M, Hirsh J, et al . A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med , 1999, 340: 901. | 
				                                                        
				                                                            
				                                                                | 13. | Campbell IA, Bentley DP, Prescott RJ, et al . Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ , 2007, 334: 674. | 
				                                                        
				                                                            
				                                                                | 14. | Kearon C, Ginsberg JS, Anderson DR, et al . Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost , 2004, 2: 743-749. | 
				                                                        
				                                                            
				                                                                | 15. | Agnelli G, Prandoni P, Santamaria MG, et al . Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med , 2001, 345: 165. | 
				                                                        
				                                                            
				                                                                | 16. | Guyatt GH, Oxman AD, Vist GE, et al . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ , 2008, 336: 924-926. |